Xoterna Breezhaler

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

indacaterol, Glycopyrronium bromid

Available from:

Novartis Europharm Limited

ATC code:

R03AL04

INN (International Name):

indacaterol, glycopyrronium bromide

Therapeutic group:

Adrenergics v kombinacijah z anticholinergics vklj. trojne kombinacije s kortikosteroidi

Therapeutic area:

Pljučna bolezen, kronična obstruktivna bolezen

Therapeutic indications:

Zdravilo Xoterna Breezhaler je indicirano za zdravljenje bronhodilatatorjev za vzdrževanje simptomov pri odraslih bolnikih s kronično obstruktivno pljučno boleznijo (KOPB).

Product summary:

Revision: 16

Authorization status:

Pooblaščeni

Authorization date:

2013-09-18

Patient Information leaflet

                                30
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
Uporabno do
Inhalator vsakega pakiranja je treba zavreči, ko porabite vse kapsule
tega pakiranja.
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte pri temperaturi do 25 °C.
Kapsule shranjujte v originalnem pretisnem omotu, da jih zaščitite
pred vlago, in jih vzemite iz
ovojnine šele tik pred uporabo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Novartis Europharm Limited
Vista Building
Elm Park, Merrion Road
Dublin 4
Irska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/13/863/001
6 kapsul + 1 inhalator
EU/1/13/863/007
10 kapsul + 1 inhalator
EU/1/13/863/002
12 kapsul + 1 inhalator
EU/1/13/863/003
30 kapsul + 1 inhalator
EU/1/13/863/004
90 kapsul + 1 inhalator
13.
ŠTEVILKA SERIJE
Serija
_ _
14.
NAČIN IZDAJANJA ZDRAVILA
Predpisovanje in izdaja zdravila je le na recept.
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Xoterna Breezhaler
31
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI
PC
SN
NN
32
PODATKI NA ZUNANJI OVOJNINI
ZUNANJA ŠKATLA SKUPNEGA PAKIRANJA (VKLJUČNO Z “BLUE BOX”
PODATKI)
1.
IME ZDRAVILA
Xoterna Breezhaler 85 mikrogramov/43 mikrogramov prašek za
inhaliranje, trde kapsule
indakaterol/glikopironij
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena kapsula vsebuje 110 mikrogramov indakaterola in 50 mikrogramov
glikopironija. Količina
inhaliranega indakaterola je 85 mikrogramov (kar ustreza 110
mikrogramom indakaterolijevega
maleata), inhaliranega glikopironija pa 43 mikrogramov (kar ustreza 54
mikrogramom
glikopironijevega bromida).
3.
SEZNAM POMOŽNIH SNOVI
Vsebuje tudi: laktozo in magnezijev stearat.
Za več podatkov glejte navodilo za uporabo.
4.
FARMACEVTSKA OBLIKA IN VSEBINA
prašek za inhaliranje, trda kapsula
Skupno pakiranje: 96 kapsul (4 pakiranja po 24 x 1) in 4 inhalatorji.
Skupno pakir
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Xoterna Breezhaler 85 mikrogramov/43 mikrogramov prašek za
inhaliranje, trde kapsule
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena kapsula vsebuje 143 mikrogramov indakaterolijevega maleata, kar
ustreza 110 mikrogramov
indakaterola, in 63 mikrogramov glikopironijevega bromida, kar ustreza
50 mikrogramov
glikopironija.
En odmerek, ki pride skozi ustnik inhalatorja, vsebuje 110 mikrogramov
indakaterolijevega maleata,
kar ustreza 85 mikrogramov indakaterola, in 54 mikrogramov
glikopironijevega bromida, kar ustreza
43 mikrogramov glikopironija.
Pomožna(e) snov(i) z znanim učinkom:
Ena kapsula vsebuje 23,5 mg laktoze (v obliki monohidrata).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
prašek za inhaliranje, trda kapsula (prašek za inhaliranje)
Kapsule z rumenim prozornim pokrovčkom in brezbarvnim prozornim
telesom. Kapsule vsebujejo bel
do skoraj bel prašek in imajo na telesu kapsule pod dvema modrima
črtama modro tiskano oznako
“IGP110.50”, na pokrovčku pa črno tiskan zaščitni znak družbe
(
).
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Xoterna Breezhaler je indicirano kot vzdrževalno
bronhodilatatorno zdravljenje za lajšanje
simptomov pri odraslih bolnikih s kronično obstruktivno pljučno
boleznijo (KOPB).
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
Priporočeni odmerek je inhalacija vsebine ene kapsule enkrat na dan z
uporabo inhalatorja Xoterna
Breezhaler.
Zdravilo Xoterna Breezhaler je priporočeno uporabiti vsak dan ob
istem času. V primeru izpuščenega
odmerka je treba zdravilo vzeti čimprej še isti dan. Bolnikom je
treba naročiti, naj ne vzamejo več kot
enega odmerka v istem dnevu.
Posebne skupine bolnikov
_Populacija starejših _
Starejši bolniki (stari 75 let ali več) lahko uporabljajo zdravilo
Xoterna Breezhaler v priporočenem
odmerku.
3
_Okvara ledvic _
Bolniki z blago do zmerno okvaro ledvic lahko uporabljajo zdravilo
Xoterna Breezhaler v
priporočenem odmerku. Bolniki
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 07-09-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 07-09-2021
Public Assessment Report Public Assessment Report Bulgarian 04-10-2013
Patient Information leaflet Patient Information leaflet Spanish 07-09-2021
Public Assessment Report Public Assessment Report Spanish 04-10-2013
Patient Information leaflet Patient Information leaflet Czech 07-09-2021
Public Assessment Report Public Assessment Report Czech 04-10-2013
Patient Information leaflet Patient Information leaflet Danish 07-09-2021
Public Assessment Report Public Assessment Report Danish 04-10-2013
Patient Information leaflet Patient Information leaflet German 07-09-2021
Public Assessment Report Public Assessment Report German 04-10-2013
Patient Information leaflet Patient Information leaflet Estonian 07-09-2021
Public Assessment Report Public Assessment Report Estonian 04-10-2013
Patient Information leaflet Patient Information leaflet Greek 07-09-2021
Public Assessment Report Public Assessment Report Greek 04-10-2013
Patient Information leaflet Patient Information leaflet English 07-09-2021
Public Assessment Report Public Assessment Report English 04-10-2013
Patient Information leaflet Patient Information leaflet French 07-09-2021
Public Assessment Report Public Assessment Report French 04-10-2013
Patient Information leaflet Patient Information leaflet Italian 07-09-2021
Public Assessment Report Public Assessment Report Italian 04-10-2013
Patient Information leaflet Patient Information leaflet Latvian 07-09-2021
Public Assessment Report Public Assessment Report Latvian 04-10-2013
Patient Information leaflet Patient Information leaflet Lithuanian 07-09-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 07-09-2021
Public Assessment Report Public Assessment Report Lithuanian 04-10-2013
Patient Information leaflet Patient Information leaflet Hungarian 07-09-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 07-09-2021
Public Assessment Report Public Assessment Report Hungarian 04-10-2013
Patient Information leaflet Patient Information leaflet Maltese 07-09-2021
Public Assessment Report Public Assessment Report Maltese 04-10-2013
Patient Information leaflet Patient Information leaflet Dutch 07-09-2021
Public Assessment Report Public Assessment Report Dutch 04-10-2013
Patient Information leaflet Patient Information leaflet Polish 07-09-2021
Public Assessment Report Public Assessment Report Polish 04-10-2013
Patient Information leaflet Patient Information leaflet Portuguese 07-09-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 07-09-2021
Public Assessment Report Public Assessment Report Portuguese 04-10-2013
Patient Information leaflet Patient Information leaflet Romanian 07-09-2021
Public Assessment Report Public Assessment Report Romanian 04-10-2013
Patient Information leaflet Patient Information leaflet Slovak 07-09-2021
Public Assessment Report Public Assessment Report Slovak 04-10-2013
Patient Information leaflet Patient Information leaflet Finnish 07-09-2021
Public Assessment Report Public Assessment Report Finnish 04-10-2013
Patient Information leaflet Patient Information leaflet Swedish 07-09-2021
Public Assessment Report Public Assessment Report Swedish 04-10-2013
Patient Information leaflet Patient Information leaflet Norwegian 07-09-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 07-09-2021
Patient Information leaflet Patient Information leaflet Icelandic 07-09-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 07-09-2021
Patient Information leaflet Patient Information leaflet Croatian 07-09-2021
Public Assessment Report Public Assessment Report Croatian 04-10-2013